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The objective of this study was to investigate the correla-
tion between factor XIII (FXIII) activity and disseminated
intravascular coagulation (DIC) parameters and also to
evaluate the clinical usefulness of DIC diagnosis. Citrated
plasma from eighty patients with potential DIC was analyzed
for FXIII activity. The primary patient conditions (48 male
and 32 female, mean age, 51 years) were malignancy (n =
29), infection (n = 25), inflammation (n = 6), heart disease
(n = 3), thrombosis (n = 2), injury (n = 2), and other miscel-
laneous conditions (n = 13). FXIII testing was performed
using the CoaLinkTM FXIII Incorporation Assay Kit
(PeopleBio Inc.). Among 80 patients who were suspected to
have DIC based on clinical analysis, 46 (57.5%) fulfilled the
overt DIC criteria (DIC score > = 5) according to the Inter-
national Society of Thrombosis and Haemostasis. FXIII
levels in the plasma were significantly decreased in overt
DIC compared to non-overt DIC patients (mean 75.1% and
199.7% respectively, p < 0.0001). Interestingly, we found a
significant inverse correlation between DIC scores and FXIII
activity. In addition, FXIII activity significantly correlated
with other hemostatic markers that included platelet count,
prothrombin time, activated partial thromboplastin time,
fibrinogen, and D-dimer. FXIII levels were significantly
lower in patients with liver or renal dysfunction. In con-
clusion, FXIII cross-linking activity measurements may have
differential diagnostic value as well as predictive value in
patients who are suspected to have DIC.
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INTRODUCTION
Factor XIII (FXIII) is a plasma protein that plays
an important role in the final stages of the clotting
cascade and the regulation of fibrinolysis.1,2 FXIII
deficiency, caused by dyspoiesis or increased con-
sumption, results in bleeding tendencies and
wound healing complications.3 Postoperative hem-
orrhage in patients with congenital and acquired
FXIII deficiency has been described in various
surgical fields.4 Low activity levels were found in
patients with various conditions such as sepsis,
multiple fractures, and disseminated intra-
vascular coagulation (DIC).5 However, little data
has been generated on the clinical relevance of
FXIII activity in the differential diagnosis of non-
overt and overt DIC. The objective of this study
was to investigate the correlation between FXIII
activity and DIC coagulation parameters, and to
evaluate the clinical usefulness of DIC diagnosis.
MATERIALS AND METHODS
The citrated plasma from 80 patients with
potential DIC were analyzed for FXIII activity.
The primary patient conditions (48 male and 32
female, mean age, 51 years) were malignancy (n=
29), infection (n = 25), inflammation (n = 6), heart
disease (n = 3), thrombosis (n = 2), injury (n = 2),
and other miscellaneous conditions (n=13) (Table
1). FXIII testing was performed using the CoaLinkTM
FXIII Incorporation Assay Kit (PeopleBio Inc., NY,
USA) according to the manufacturer's instruc-
tions. The assay kit is designed to quantitate the
true functional FXIII and FXIIIa activity in plasma
by measuring transglutaminase activity. In this
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assay, the thrombin-activated FXIIIa from the
patient plasma binds to a substrate coated plate.
Next, a horse radish peroxidase (HRP)-conjugated
FXIII is cross-linked to the captured FXIIIa. The
cross-linked HRP is then detected with a HRP
chromogenic substrate at 450 nm. The data was
analyzed to evaluate the correlation between
FXIII activity and other DIC markers which in-
cluded platelet count, fibrinogen activities, pro-
thrombin time (PT), activated partial throm-
boplastin time (APTT), and fibrin degradation
product (D-dimer). PT, APTT, fibrinogen, and
D-dimer results were generated with an auto-
mated clotting analyzer (STA-R) using reagents
from Diagnostica Stago (Asnieres, France). Com-
parisons of mean group values were performed
using a Student's t-test. The Pearson correlation
coefficients (r) were calculated to evaluate the
relationship of FXIII with other hemostatic
markers. A value of p < 0.05 was considered to be
statistically significant.
RESULTS
Among the 80 patients who, upon clinical ex-
amination, potentially had DIC, 46 (57.5%) ful-
filled the overt DIC criteria (DIC score > = 5) ac-
cording to the ISTH (International Society of Throm-
bosis and Haemostasis) scoring system.6 Patient
characteristics at the time of study entry are shown
in Table 2. The plasma levels of FXIII was signi-
ficantly decreased in overt DIC patients (mean,
75.1%) compared to non-overt DIC patients (mean,
199.7%) (p < 0.0001, Table 3). DIC scores were in-
versely correlated to FXIII activity (p < 0.0001, Table
4). In addition, FXIII activity was significantly cor-
related to other hemostatic markers including
platelet count (r = 0.2560, p = 0.0191), PT (r = - 0.3659,
p = 0.0007), APTT (r = - 0.3058, p = 0.0052), fibrinogen
(r = 0.5887, p < 0.0001), and D-dimer (r = - 0.3030, p=
0.0057). In contrast, FXIII activity did not signi-
ficantly correlate with antithrombin levels. The
FXIII levels were significantly lower in patients
with liver or renal dysfunction than those without
organ dysfunction (p = 0.0064, p = 0.0473, respec-
tively). However, no significant difference in FXIII
levels was detected when we compared patients
with infections to patients without infections
(Table 5).
Table 2. Hemostatic Markers in Patients with Overt and Non-overt DIC
Overt DIC Non-overt DIC p value
DIC score 6.2 ± 0.8 2.8 ± 1.3 < 0.0001
Platelet count (/ L)μ 69,000 ± 40,000 173,000 ± 98,000 < 0.0001
PT (sec) 29.9 ± 14.2 17.7 ± 3.8 < 0.0001
PT (INR) 3.3 ± 2.4 1.5 ± 0.42 < 0.0001
APTT (sec) 83.8 ± 45.0 55.5 ± 26.4 0.0003
Fibrinogen (mg/dL) 188 ± 167 407 ± 208 < 0.0001
D-dimer ( g/mL)μ 34.6 ± 40.4 10.7 ± 17.1 0.0003
Antithrombin (%) 46.7 ± 27.3 58.5 ± 22.3 0.0339
DIC, disseminated intravascular coagulation; PT, prothrombin time; APTT, activated partial thromboplastin time.
Table 1. Characteristics of the Study Population
Age (yrs, mean ± SD) 51 ± 17
Male: Female 48 : 32
Underlying disease n
Malignancy 29
Infection* 25
Inflammation 6
Heart disease 3
Thrombosis 2
Injury 2
Miscellaneous 13
*29 cases, including 4 secondary infections.
SD, standard deviation.
Table 5. Percentages of Plasma Factor XIII Activity in Patients with Infection, Liver Dysfunction, or Renal
Dysfunction
Factor XIII Activity (%)
n Mean (SD) Range p value
Infection
Yes
No
29
51
160.3 (190.6)
109.6 (90.5)
7.6 - 1007.1
0.0 - 327.3
0.2373
Liver dysfunction
Yes
No
50
30
107.7 (148.8)
162.0 (107.3)
0.0 - 1007.1
0.0 - 376.5
0.0064
Renal dysfunction
Yes
No
20
60
80.7 (74.4)
143.8 (149.0)
0.0 - 1007.1
0.0 - 309.6
0.0473
PT, prothrombin time; APTT, activated partial thromboplastin time; Fg, fibrinogen.
DD, D-dimer; AT, antithrombin; DIC, disseminated intravascular coagulation.
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Table 3. Plasma Factor XIII activity in Patients with Disseminated Intravascular Coagulation (DIC)
Study Group
Factor XIII Activity (%)
n Mean (SD) Range
Total Patients* 80 127.5 (135.0) 0.0 - 1007.1
Non-overt DIC 34 199.7 (170.0) 10.3 - 1007.1
Overt DIC 46 75.1 (69.5) 0.0 - 285.0
Non-overt DIC vs. Overt DIC*, p value < 0.0001.
Table 4. Correlations (r) between Factor XIII Activity and DIC Coagulation Parameters (p value)
FXIII (%) Platelets ( L)μ PT (sec) APTT (sec) Fg (mg/dL) DD ( g/mL)μ AT (%)
Platelets ( L)μ 0.2560
(.0191)
*
PT (sec) - 0.3659
(.0007)
- 0.2245
(.0426)
*
APTT (sec) - 0.3058
(.0052)
- 0.1364
(.2219)
0.6882
(< .0001)
*
Fg (mg/dL) 0.5887
(<.0001)
0.3418
(.0018)
- 0.4004
(< .0001)
- 0.3414
(.0017)
*
DD ( g/mL)μ - 0.3030
(.0057)
- 0.2248
(.0424)
0.1520
(.1701)
0.2457
(.0251)
- 0.3011
(.0060)
*
AT (%) 0.1771
(.1160)
0.1853
(.0999)
- 0.4026
(.0002)
- 0.3259
(.0027)
0.3320
(.0026)
0.1511
(.1783)
*
DIC (Score) -0.5648
(< .0001)
- 0.5429
(< .0001)
0.5791
(< .0001)
0.5298
(< .0001)
- 0.4888
(< .0001)
0.4449
(< .0001)
- 0.2023
(.0701)
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DISCUSSION
In this study, FXIII plasma activity is compared
with other hemostatic markers in a group of
patients with a clinical potential for DIC. Of the
80 patients in this study, 46 (57.5%) patients were
diagnosed with overt DIC as determined by a DIC
score > = 5, according to the ISTH scoring system.
FXIII activity was highly variable, but decreased
significantly in overt DIC patients compared with
non-overt DIC patients. We detected a significant
correlation between FXIII activity and global co-
agulation tests, such as platelet counts, PT, APTT,
and fibrinogen. Interestingly, these tests are also
important for the diagnosis of DIC. These results
suggest that measuring FXIII activity may be
helpful in diagnosing overt DIC.
FXIII activity was significantly correlated to
DIC score, suggesting that the measurement of
FXIII activity could be a clinically useful pro-
gnostic marker for DIC. FXIII circulates as an
intact zymogen composed of a tetramer of paired
A- and B- subunits and becomes enzymatically
active after thrombin or factor Xa activation. The
peptide responsible for enzymatic activation is
located in the A subunit.7 In this study, we used
the true functional assay of transglutaminase
activity to determine the levels of FXIII incor-
poration.
Lower FXIII activity in overt-DIC patients
compared to non-overt DIC patients in this study
may reflect a decreased number of A subunits as
the result of a state of consumptive coagulopathy.
In DIC cases which improved after treatment, the
ratio of A to B subunits has been reported to be
between 0.5 and 1.0. These ratios were less than
0.5 in cases of DIC that deteriorated in spite of
treatment.8 A functional ELISA-based FXIII incor-
poration assay may be a good alternative to using
two separate ELISA systems to measure FXIII A
and B subunit ratios. In addition, this functional
assay may have prognostic value as a predictive
marker for DIC.
DIC occurs frequently as a complication of
severe sepsis and other conditions,
9
contributes to
the pathogenesis of multiple organ dysfunctions,
and is an independent predictor of mortality.10
Recent advances in our understanding of DIC
pathogenic mechanisms have resulted in novel
therapeutic approaches, such as the administra-
tion of activated human protein C in order to
restore physiologic pathways.11 In this study, FXIII
is associated with renal dysfunction and may have
clinical implications in the treatment of patients
with both DIC and organ dysfunction. Hypotheti-
cally, a combination of overt DIC and low FXIII
activity may provide one of the new therapeutic
strategies aimed at reducing mortality or the
sepsis-related organ failure assessment (SOFA)
score. There are several reports documenting the
success of using FXIII in conjunction with anti-
thrombin concentrate or antiplasmin drugs to
treat patients with life-threatening DIC and
decreased FXIII activity.12,13
In this study, FXIII activity was found to be
associated with liver dysfunction. Because FXIII is
synthesized in the liver, impaired synthesis could
lead to acquired FXIII deficiency in acute or
chronic liver failure, as previously described.14
The mean FXIII activity (107.7%) in patients with
liver dysfunction was only slightly decreased com-
pared to healthy subjects (121.3%, ranging from
40.5% to 196%, SD, 28.9, n = 100). This finding
supports that FXIII is synthesized not only in the
liver but also in other cells, including platelets and
monocytes.15,16 These cell-associated FXIII mole-
cules could also be one of the regulating factors
of plasma FXIII activity and the cross-linking of
fibrin that is associated with DIC pathogenesis.
In conclusion, we found a significant difference
in plasma FXIII activity between patients with
overt DIC and non-overt DIC. The measurement
of FXIII cross-linking activity may have differen-
tial diagnostic value as well as predictive value in
patients suspected to have DIC. FXIII concentrate
could be used beneficially as an adjunct in
therapeutic intervention.
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